Moderna, Merck cancer vaccine shows promise in late-stage trial; Moderna stock soars 90%
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC